Group 1 - The core point of the article is that Everbright Tongchuang (SZ 301387) held its 12th meeting of the second board on October 24, 2025, to review the proposal for the "2025 Q3 Report" [1] - For the first half of 2025, Everbright Tongchuang's revenue composition was as follows: functional products accounted for 56.8%, protective products accounted for 40.54%, and others accounted for 2.65% [1] - As of the report date, Everbright Tongchuang's market capitalization was 4.4 billion yuan [1] Group 2 - The article mentions that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year [1] - There is a discussion on the hot secondary market for biomedicine, while the primary market is facing challenges in fundraising [1]
光大同创：10月24日召开董事会会议